Coya Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $114.2M
- Price
- $4.87
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.21%
- Volume
- 70.9K
About
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Quick stats
Shares outstanding23.5M
Computed float18.3M
Float / shares77.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001835022
AI Summary
AI-generated1/18
standardmixedearnings
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Coya Therapeutics reported a Q2 net loss of $6.6 million, or $(0.28) per share, compared to a loss of $6.1 million in the prior year, with collaboration revenue flat at $0.2 million.
The company holds $43.2 million in cash and cash equivalents, sufficient to fund operations into the second half of 2027, extending past the expected topline data readout for its Phase 2 ALSTARS trial in Q1 2027.
Operational highlights include progress in the ALSTARS trial, the receipt of FDA Fast Track Designation for COYA 302, and the appointment of Mark H. Pavao as Independent Director.
Red flags
- Net loss widened to $6.6 million from $6.1 million year-over-year
- R&D expenses increased 35% to $5.0 million, increasing cash burn